Associate Professor of Medicine, Vanderbilt University
Hematology
Dr. Jill Gilbert, MD
|
|
Give Review
Jill Gilbert, MD is an expert in the field of Hematology. She attended University of Alabama Medical Center. University of Alabama Medical Center has a rank of 37 in research and a 17 in primary care Jill Gilbert, MD has written publications. She has 31 publications published with PubMed. The lastest publication is: 'Using the galactose--1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab.' Jill Gilbert accepts all Medicare patients.
Publications
- A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced s...
- Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
- A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
- Preliminary Testing of a Patient-Reported Outcome Measure for Recurrent or Metastatic Head and Neck Cancer.
- A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
- Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation...
- Patient Enrollment onto Clinical Trials: the Role of Physician Knowledge.
- Head and Neck Cancers, Version 2.2013.
- Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology ...
- Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of ...
- Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life.
- Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health.
- Outcome analysis of patients with squamous cell carcinoma of the head and neck and hepatitis C virus.
- Prevalence and epidemiology of hepatitis C virus in patients with squamous cell carcinoma of the head and neck.
- Factors associated with the career choices of hematology and medical oncology fellows trained at academic institutions in the United States.
- Head and neck cancers.
- Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer.
- Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.
- Evolution of clinical trials in head and neck cancer.
- Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
- Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation.
- Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer.
- Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene.
- Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
- Oral cancers: supportive care issues.
- Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation.
- Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
- Symptom control issues and supportive care of patients with head and neck cancers.
- Systemic and global toxicities of head and neck treatment.
- Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab.
Schools
University Of Alabama School Of Medicine
Johns Hopkins University School Med
University Of Al Hospital
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Johns Hopkins University -
University of Alabama Medical Center -
University of Alabama School of Medicine
Hospital
-
Vanderbilt Hospital and Clinics
Helpful Reviews
Similar Doctors
|
Dr. Jordan D. Berlin, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Vicki L. Keedy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristin K. Ancell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William Pao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary Ann Arildsen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Gailani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mace L. Rothenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kent C. Shih, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul B. Ferrell Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew J. Rioth, MD |
|
|
Dr. Mohammad H. Rashid, MD |